Jun-Seop Shin1,2,3,4, Jong-Min Kim1,3,4, Byoung-Hoon Min1,3,4, Il Hee Yoon1,2,4, Hyun Je Kim1,2,4,5, Jung-Sik Kim1,2,3,4, Yong-Hee Kim1,2, Seong-Jun Kang1,2,4,5, Jiyeon Kim1,2, Hee-Jung Kang6, Dong-Gyun Lim7, Eung-Soo Hwang1,2, Jongwon Ha8, Sang-Joon Kim1,9, Wan Beom Park10, Chung-Gyu Park1,2,3,4,5,11. 1. Xenotransplantation Research Center, Seoul National University, College of Medicine, Seoul, Korea. 2. Department of Microbiology and Immunology, Seoul National University, College of Medicine, Seoul, Korea. 3. Institute of Endemic Diseases, Seoul National University, College of Medicine, Seoul, Korea. 4. Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea. 5. Department of Biomedical Sciences, Seoul National University, College of Medicine, Seoul, Korea. 6. Department of Laboratory Medicine, Hallym University College of Medicine, Anyang, Korea. 7. National Medical Centre, Seoul, Korea. 8. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. 9. Myong-Ji Hospital, Koyang-si, Kyeonggi-do, Korea. 10. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. 11. Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Abstract
BACKGROUND: Islet transplantation is an effective therapy for selected patients with type 1 diabetes with labile glycemic control and hypoglycemic unawareness, but donor organs are limited. Islet xenotransplantation using porcine islets will potentially solve this problem. Although successful proof of concept studies using clinically inapplicable anti-CD154 monoclonal antibody (mAb) in pig-to-non-human primate (NHP) islet xenotransplantation has been demonstrated by several groups worldwide, potentially clinically applicable anti-CD40 (2C10R4) mAb-based studies have not been reported. METHODS: Nine streptozotocin (STZ)-induced diabetic rhesus monkeys were transplanted with adult porcine islets isolated from designated pathogen-free (DPF) miniature pigs. They were treated with anti-CD40 mAb-based immunosuppressive regimen and were divided into 3 groups: anti-CD40 only group (n = 2), belatacept group (anti-CD40 mAb+belatacept, n = 2), and tacrolimus group (anti-CD40 mAb+tacrolimus, n = 5). All monkeys received anti-thymocyte globulin (ATG), cobra venom factor (CVF), adalimumab, and sirolimus. Blood glucose levels (BGL) and serum porcine C-peptide concentrations were measured. Humoral and cellular immune responses were assessed by ELISA and ELISPOT, respectively. Liver biopsy and subsequent immunohistochemistry were conducted. RESULTS: All animals restored normoglycemia immediately after porcine islet transplantation and finished the follow-up without any severe adverse effects except for one animal (R092). Most animals maintained their body weight. Median survival, as defined by a serum porcine C-peptide concentration of >0.15 ng/mL, was 31, 27, and 60 days for anti-CD40 only, belatacept, and tacrolimus groups, respectively. Anti-αGal IgG levels in serum and the number of interferon-γ secreting T cells in peripheral blood mononuclear cells did not increase in most animals. CONCLUSION: These results showed that anti-CD40 mAb combined with tacrolimus was effective in prolonging porcine islet graft survival, but anti-CD40 mAb was not as effective as anti-CD154 mAb in terms of preventing early islet loss.
BACKGROUND: Islet transplantation is an effective therapy for selected patients with type 1 diabetes with labile glycemic control and hypoglycemic unawareness, but donor organs are limited. Islet xenotransplantation using porcine islets will potentially solve this problem. Although successful proof of concept studies using clinically inapplicable anti-CD154 monoclonal antibody (mAb) in pig-to-non-human primate (NHP) islet xenotransplantation has been demonstrated by several groups worldwide, potentially clinically applicable anti-CD40 (2C10R4) mAb-based studies have not been reported. METHODS: Nine streptozotocin (STZ)-induced diabetic rhesus monkeys were transplanted with adult porcine islets isolated from designated pathogen-free (DPF) miniature pigs. They were treated with anti-CD40 mAb-based immunosuppressive regimen and were divided into 3 groups: anti-CD40 only group (n = 2), belatacept group (anti-CD40 mAb+belatacept, n = 2), and tacrolimus group (anti-CD40 mAb+tacrolimus, n = 5). All monkeys received anti-thymocyte globulin (ATG), cobra venom factor (CVF), adalimumab, and sirolimus. Blood glucose levels (BGL) and serum porcine C-peptide concentrations were measured. Humoral and cellular immune responses were assessed by ELISA and ELISPOT, respectively. Liver biopsy and subsequent immunohistochemistry were conducted. RESULTS: All animals restored normoglycemia immediately after porcine islet transplantation and finished the follow-up without any severe adverse effects except for one animal (R092). Most animals maintained their body weight. Median survival, as defined by a serum porcine C-peptide concentration of >0.15 ng/mL, was 31, 27, and 60 days for anti-CD40 only, belatacept, and tacrolimus groups, respectively. Anti-αGalIgG levels in serum and the number of interferon-γ secreting T cells in peripheral blood mononuclear cells did not increase in most animals. CONCLUSION: These results showed that anti-CD40 mAb combined with tacrolimus was effective in prolonging porcine islet graft survival, but anti-CD40 mAb was not as effective as anti-CD154 mAb in terms of preventing early islet loss.
Authors: A Page; S Srinivasan; K Singh; M Russell; K Hamby; T Deane; S Sen; L Stempora; F Leopardi; A A Price; E Strobert; K A Reimann; A D Kirk; C P Larsen; L S Kean Journal: Am J Transplant Date: 2011-09-19 Impact factor: 8.086
Authors: J S Shin; J M Kim; J S Kim; B H Min; Y H Kim; H J Kim; J Y Jang; I H Yoon; H J Kang; J Kim; E S Hwang; D G Lim; W W Lee; J Ha; K C Jung; S H Park; S J Kim; C G Park Journal: Am J Transplant Date: 2015-06-10 Impact factor: 8.086
Authors: P Thompson; K Cardona; M Russell; I R Badell; V Shaffer; G Korbutt; G R Rayat; J Cano; M Song; W Jiang; E Strobert; R Rajotte; T Pearson; A D Kirk; C P Larsen Journal: Am J Transplant Date: 2011-05 Impact factor: 8.086
Authors: Bernhard J Hering; William R Clarke; Nancy D Bridges; Thomas L Eggerman; Rodolfo Alejandro; Melena D Bellin; Kathryn Chaloner; Christine W Czarniecki; Julia S Goldstein; Lawrence G Hunsicker; Dixon B Kaufman; Olle Korsgren; Christian P Larsen; Xunrong Luo; James F Markmann; Ali Naji; Jose Oberholzer; Andrew M Posselt; Michael R Rickels; Camillo Ricordi; Mark A Robien; Peter A Senior; A M James Shapiro; Peter G Stock; Nicole A Turgeon Journal: Diabetes Care Date: 2016-04-18 Impact factor: 19.112
Authors: Gil Hecht; Smadar Eventov-Friedman; Chava Rosen; Elias Shezen; Dalit Tchorsh; Anna Aronovich; Enrique Freud; Hana Golan; Ronit El-Hasid; Helena Katchman; Bernhard J Hering; Amnon Zung; Zipi Kra-Oz; Pninit Shaked-Mishan; Alex Yusim; Alex Shtabsky; Pavel Idelevitch; Ana Tobar; Alon Harmelin; Esther Bachar-Lustig; Yair Reisner Journal: Proc Natl Acad Sci U S A Date: 2009-05-11 Impact factor: 11.205
Authors: Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Marvin L Thomas Iii; Tannia Clark; Billeta G Lewis; Robert F Hoyt; Michael Eckhaus; Richard N Pierson Iii; Aaron J Belli; Eckhard Wolf; Nikolai Klymiuk; Carol Phelps; Keith A Reimann; David Ayares; Keith A Horvath Journal: Nat Commun Date: 2016-04-05 Impact factor: 14.919
Authors: David K C Cooper; Jeremy B Foote; Mariyam Javed; Huy Q Nguyen; Mohamed H Bikhet; Christophe Hansen-Estruch; David Ayares; Hidetaka Hara Journal: Xenotransplantation Date: 2021-11-30 Impact factor: 3.907
Authors: Wayne J Hawthorne; Evelyn J Salvaris; Yi Vee Chew; Heather Burns; Joanne Hawkes; Helen Barlow; Min Hu; Andrew M Lew; Mark B Nottle; Philip J O'Connell; Peter J Cowan Journal: Front Immunol Date: 2022-06-16 Impact factor: 8.786